



IDH1/2, General AML

Eunice Wang | ASCO 2018 | What are the new advances in AML treatment?

 Cynthia Umukoro | Jun 04, 2018

At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Eunice S. Wang from Roswell Park Comprehensive Cancer Center, Buffalo, NY, talks about novel agents including ivosidenib, an oral targeted inhibitor of mutant *IDH1*, and venetoclax, a BCL-2 inhibitor which have both demonstrated promising results in patients with acute myeloid leukemia (AML).

© 2018 Scientific Education Support Ltd. This PDF is provided for personal use only. For wider or commercial use, please seek permission from secretariat@scientificeducationsupport.com and attribute the source as: <<http://www.amlglobalportal.com/medical-information/eunice-wang-asco-2018-what-are-the-new-advances-in-aml-treatment>>